肌层浸润性膀胱癌患者新辅助化疗及根治性膀胱切除术后1年无复发生存建模:2期试验终点
该多中心回顾性队列纳入1990至2016年间27个中心950例cT2-4N0M0肌层浸润性膀胱癌根治性膀胱切除术患者,评估围手术期化疗对1年无复发生存的影响并建立列线图。模型c-index为0.76,列线图三分位组1年无复发生存率分别为90.5%、73.4%和51.1%,结果缺乏外部验证。
要点
- 无围手术期化疗、新辅助化疗、辅助化疗、新辅助+辅助化疗后1年无复发生存率分别为67.9%、76.9%、77.8%、57%。
- 多变量分析中手术切缘阳性、pT分期、pN分期与无复发生存显著相关,新辅助化疗无显著关联。
- 列线图三分位组1年无复发生存率分别为90.5%、73.4%、51.1%。
核心结论
- 提出用于2期新辅助试验设计统计假设的1年无复发生存基准估计值,有待外部验证。
研究设计与样本
- 多中心回顾性队列研究,纳入1990至2016年间27个中心的950例cT2-4N0M0肌层浸润性膀胱癌行根治性膀胱切除术患者。
主要发现
- 1年无复发生存率:无围手术期化疗67.9%(95%CI 64-72),新辅助化疗76.9%(95%CI 72-83%),辅助化疗77.8%(95%CI 71-85%),新辅助+辅助化疗57%(95%CI 37-87)。
- 多变量分析显示手术切缘阳性(p=0.002)、pT分期(p<0.0001)、pN分期(p<.0001)与无复发生存显著相关,新辅助化疗无显著关联(p=0.6)。
- 包含上述因素的模型c-index为0.76(95%CI 0.72-0.79),校准良好且净获益高。
- 列线图三分位组1年无复发生存率分别为90.5%(95%CI 87-94%)、73.4%(95%CI 68-79%)、51.1%(95%CI 45-58%)。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 结果缺乏外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several ongoing phase 2 trials are evaluating new neoadjuvant therapy regimens in patients with muscle-invasive bladder cancer (MIBC). The 1-yr recurrence-free survival (RFS) after radical cystectomy (RC), with or without perioperative chemotherapy, can be used to model statistical assumptions and interpret outcomes from these studies. OBJECTIVE: To provide a benchmark for predicting 1-yr RFS in patients with cT2-4N0 MIBC. DESIGN, SETTING, AND PARTICIPANTS: We identified 950 patients with clinical stage T2-4N0 MIBC undergoing RC at 27 centers between 1990 and 2016. We assessed 1-yr RFS rates for patients managed with no perioperative chemotherapy, neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), or NAC followed by AC. Cox regression analyses tested for 1-yr postsurgical RFS predictors. A Cox-based nomogram was developed to estimate 1-yr RFS and its accuracy was assessed in terms of Harrell's c-index, a calibration plot, and decision curve analysis. We report 1-yr RFS rates across the nomogram tertiles. RESULTS AND LIMITATIONS: The 1-yr RFS rates were 67.9% (95% confidence interval [CI] 64-72) after no perioperative chemotherapy, 76.9% (95% CI 72-83%) after NAC, 77.8% (95% CI 71-85%) after AC, and 57% (95% CI 37-87) after NAC+AC. On multivariable analysis, positive surgical margins (p=0.002), pT stage (p<0.0001), and pN stage (p<.0001) were significantly associated with RFS, while NAC was not (p=0.6). The model including all these factors yielded a c-index of 0.76 (95% CI 0.72-0.79), good calibration, and a high net benefit. The 1-yr RFS rates across nomogram tertiles were 90.5% (95% CI 87-94%), 73.4% (95% CI 68-79%), and 51.1% (95% CI 45-58%), respectively. The results lack external validation. CONCLUSIONS: Benchmark 1-yr RFS estimates for phase 2 design of new neoadjuvant trials are proposed and can be used for statistical assumptions, pending external validation. PATIENT SUMMARY: Our prognostic model predicting 1-yr survival free from recurrence of bladder cancer after radical cystectomy, with or without standard chemotherapy, could provide an improvement to the quality of phase 2 clinical trial designs and interpretation of their results.
引用
- Bandini M, Briganti A, Plimack ER, et al. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Eur Urol Oncol. 2018. PMID: 31200838. doi:10.1016/j.euo.2018.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。